

PRESS RELEASE

18 April 2023 09:11:00 CEST

New US data confirms that TetraGraph supports clinical decisions and assures patient safety

Recently presented abstract validates that the EMG-based TetraGraph is comparable to the laboratory standard technology MMG during all depths of neuromuscular blockade, confirming TetraGraph's ability to assist in clinical decisions and to assure patient safety from start to finish during surgery.

Uppsala, Sweden, April 18, 2023. Senzime AB (publ) today announced that the abstract *Validating Clinically Important Neuromuscular Monitoring Endpoints: Mechanomyography (MMG) vs. Electromyography (EMG)*, presented at the annual International Anesthesia Research Society (IARS) meeting in Denver, Colorado, US, concludes that a comparison of the EMG-based TetraGraph neuromuscular monitor to the laboratory standard technology mechanomyogram (MMG) shows that key clinical endpoints for neuromuscular monitoring to assist in clinical decisions and to assure patient safety, correlates well.

Historically MMG has been considered the laboratory “gold standard” for monitoring neuromuscular function during anesthesia, although it is not commercially available. Determining the relationship between clinical results obtained with different technologies is important for dose and timing of neuromuscular blocking agents (NMBA) and antagonism, and for ensuring adequate recovery prior to extubation. Because of this, it is important to validate newer technologies, such as the EMG-based TetraGraph, for clinical adoption and patient safety.

“It is reassuring to see data that confirms the high quality of TetraGraph. Clinically driven innovation is part of our DNA at Senzime, and we are working closely with key hospitals and clinicians to continuously improve our products. Since this comparison was made, we have launched a new enhanced version of the unique algorithms powering TetraGraph, further supporting clinical decisions to ensure patient safety,” said Pia Renaudin, CEO of Senzime.

The clinical validation presented in the abstract *Validating Clinically Important Neuromuscular Monitoring Endpoints: Mechanomyography (MMG) vs. Electromyography (EMG)* was conducted at the Department of Anesthesiology at the Medical College of Wisconsin and at the CJ Zablocki VA Medical Center in Milwaukee, Wisconsin.

About TetraGraph®

TetraGraph is a quantitative neuromuscular monitor, based on the gold standard electromyography (EMG) technology which provides accurate and versatile monitoring of neuromuscular blockade. The product is designed to meet the needs of monitoring physiological data during surgery of patients receiving general anesthesia and muscle relaxation using muscle paralyzing drugs. TetraGraph stimulates the patient's peripheral nerve using the TetraSens® disposable sensors and measures, analyzes, and displays the muscle's potential in real time. Thanks to its small size and versatile features, TetraGraph can be used in any type of surgery, anywhere in the hospital environment, and can be connected to external monitors and electronic hospital records.

For further information, please contact:

Pia Renaudin, CEO of Sensime AB

Phone: +46 (0) 708 13 34 17, e-mail: pia.renaudin@sensime.com

Paula Treutiger, Head of Communication and IR

Phone: +46 (0) 733 66 65 99, e-mail: paula.treutiger@sensime.com

About Sensime

Sensime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Sensime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Sensime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at sensime.com.

Attachments

New US data confirms that TetraGraph supports clinical decisions and assures patient safety